ArrePath in Princeton, NJ revealed a $20m seed financing on 3 March that the company will use to advance its machine-learning based platform for discovering new classes of anti-infective drugs that can overcome antimicrobial resistance. The Boehringer Ingelheim Venture Fund, Insight Partners and Innospark Ventures co-led the seed round. ArrePath also announced that it hired formed Evotec SE executive vice president and head of anti-infectives Lloyd Payne as its CEO. Payne was CEO of anti-infective drug discovery and development firm Euprotec Ltd. when it was acquired by Evotec in 2013. (Also see "Evotec Leverages Infectious Diseases Space With Sanofi R&D Deal" - Scrip, 9 March, 2018.) He currently serves as a member of the Novo REPAIR Impact Fund scientific selection board and the AMR Action Fund scientific advisory board. (Also see "Global ‘Talent Contest’ Seeks To Spur AMR Innovation" - Scrip, 29 June, 2020.)

Finance Watch: Atlas Raises $450m Venture Fund For Biotech Breakthroughs

VC Cash Continues To Flow Despite Public Market Woes

More from Financing

More from Business